2024-10-15 - Analysis Report
## Regeneron Pharmaceuticals Inc (REGN) Stock Analysis

**Company Overview:** Regeneron Pharmaceuticals Inc is a leading biotechnology company focused on developing and commercializing life-changing medicines for serious diseases. 

**1. Performance Comparison:**

* **Cumulative Return (REGN):** 93.48%
* **Cumulative Return (VOO):** 135.82%
* **Performance Gap:** -42.34%
* **Relative Performance Gap:** 33.67% (This means that REGN's performance is currently at the 33.67 percentile compared to its historical performance range relative to VOO).

**2. Recent Price Movement:**

* **Closing Price:** $1015.67
* **5-day Moving Average:** $1005.86
* **20-day Moving Average:** $1059.31
* **60-day Moving Average:** $1108.75

**3. Technical Indicators:**

* **RSI:** 31.62 (Suggests the stock is in oversold territory)
* **PPO:** -0.34 (Indicates downward momentum)
* **Delta_Previous_Relative_Divergence:** -25.78 (Indicates short-term downward trend)
* **Expected Return:** 0.0% (This represents the potential 5-year expected return based on current investment, exceeding S&P 500, VOO).

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.7 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

The most recent earnings report (2024-08-01) showed EPS of 13.25, exceeding analyst expectations. This suggests that Regeneron is continuing to perform well despite recent market volatility.

**5. News and Recent Issues:**

**Recent Market Outlook:** While REGN is currently trading below its moving averages, it has shown resilience in recent quarters, maintaining strong earnings and revenue growth. However, the broader market uncertainty and rising interest rates might continue to impact the stock's short-term performance.

**Analyst Opinions and Performance Highlights:**  
* **FINBOLD:** Analysts are generally bullish on REGN, with an average price target of $1150. 
* **Performance Highlights:** Key drivers for REGN's growth include the success of Eylea, a drug for wet age-related macular degeneration, and Dupixent, a treatment for atopic dermatitis.

**6. Overall Analysis:**

Regeneron Pharmaceuticals is a strong player in the biotechnology sector with a proven track record of innovation and growth. While recent price action reflects market volatility, strong fundamentals and positive analyst sentiment indicate potential for future gains. The RSI suggests the stock is oversold, potentially indicating a buying opportunity for long-term investors. However, it's crucial to monitor market conditions and company-specific news for informed decision-making.

**7.  Report in English:**

This report provides an overview of Regeneron Pharmaceuticals Inc (REGN) stock. It analyzes its recent performance compared to the S&P 500, examines technical indicators, discusses recent earnings and outlook, and provides a summary of current news and analyst opinions. 

While REGN's performance has lagged behind the broader market in the short term, its solid fundamentals and strong growth prospects offer potential for future gains. However, investors should consider current market uncertainty and company-specific news before making investment decisions. 
